[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607939":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":64,"collaborators":67,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Columbia University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: Hereditary cancer testing","EXPERIMENTAL","Hereditary Cancer screenings testing and Obstetric Cancer Screening",[13,14],"Device: Natera empower comprehensive hereditary cancer panel","Device: Obstetrical carrier screening",{"label":16,"type":17,"description":18,"interventionNames":19},"Arm B: No hereditary caner testing","ACTIVE_COMPARATOR","Obstetric Cancer screening test only",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Natera empower comprehensive hereditary cancer panel","Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Obstetrical carrier screening","Obstetrical carrier screening for genetic conditions",[9,16],[32],{"name":33,"affiliation":5,"role":34},"Shayan Dioun, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jessica Giordano","CONTACT","212-305-7250","jlg2197@cumc.columbia.edu",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Reena Vattakalam","212-342-6895","rmv2110@cumc.columbia.edu",[46],{"facility":47,"status":48,"city":49,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Columbia University Irving Medical Center","RECRUITING","New York","10032","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-74.00597,40.71427,{"lat":57,"lon":56},[60,61,63],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":62,"role":38,"phone":43,"phoneExt":26,"email":44},"Reena M Vattakalam",{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":34,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Shayan M. Dioun","Assistant Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology",[68],{"name":69,"class":70},"Natera, Inc.","INDUSTRY","100607939","feasibility-trial-of-combination-of-obstetrical-carrier-screening-and-hereditary-cancer-screening-100607939",false,"NCT07195071","Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening","FOCUS","Inclusion criteria:\n\n* Age: 18 years - 55 years\n* Patients receiving obstetrical-related care at a CUMC-affiliated enrollment site\n* Patients who have elected to undergo OCS with the CUMC-affiliated obstetrics provider\n* Patients with prior OCS but planned to repeat OCS are eligible\n* Patients can speak and read in English or Spanish\n\nExclusion criteria:\n\n* Patients who have previously completed a multigene hereditary cancer syndrome panel\n* Patients that have a hematologic cancer or hematologic pre-cancer\n* Patients who have a history of an autologous bone marrow transplant",true,"FEMALE","18 Years","55 Years",{"count":83,"type":84},1000,"ESTIMATED","INTERVENTIONAL",[87],"NA","The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention",[90],"Hereditary Cancer Syndrome",[92,93,94,95,96,97,98],"obstetrical carrier screening","Pregnant women","prenatal screening","carrier screening","genetic testing","hereditary cancer","hereditary cancer genetic testing","2026-02-16",{"date":101,"type":102},"2026-02-18","ACTUAL",{"date":104,"type":102},"2026-02-12",{"date":106,"type":84},"2028-12-31",{"name":5,"class":6},1]